Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | EVP, Chief Medical Officer | June 10, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date June 10, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,500 |
Reported balance
After 2024-06-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-06-10 · Exercise / conversion · Acquired 112,500 · Balance 112,500 |
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2024-06-10 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-06-10 · Exercise / conversion · Acquired 20,000 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | Direct | 155,400 |
Reported balance
After 2024-06-10 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-06-10 · Exercise / conversion · Acquired 155,400 · Balance 155,400 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-06-10 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2024-06-10 · Sale · Disposed 287,900 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2032-02-15 | Direct | 87,500 |
Reported balance
After 2024-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-10 · Exercise / conversion · Disposed 112,500 · Balance 87,500 F2: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 112,500 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2024-06-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-10 · Exercise / conversion · Disposed 20,000 · Balance 0 F3: Option fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2030-02-11 | Direct | 0 |
Reported balance
After 2024-06-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-10 · Exercise / conversion · Disposed 155,400 · Balance 0 F3: Option fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 112,500 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company.
F3: Option fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 155,400 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · derivative · entry 7 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,400 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option fully vested. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · derivative · entry 6 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option fully vested. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · derivative · entry 5 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 112,500 shares Expires 2032-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 112,500 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 287,900 | $4.63 | $1,334,128.60 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · nonDerivative · entry 4 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 155,400 | $1.30 | $201,243.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · nonDerivative · entry 3 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 20,000 | $1.06 | $21,200.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · nonDerivative · entry 2 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 112,500 | $1.06 | $119,250.00 |
DisclosureSEC source: 0000950170-24-072420 · ownership.xml · nonDerivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000950170-24-070622 · ownership.xml · derivative · entry 2 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-07-07 F2 · derivative.exercise_date: Performance-based stock option granted on July 9, 2022 and vested in full on June 6, 2024 upon approval by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-24-070622 · ownership.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: Performance-based stock option granted on February 16, 2022 and vested in full on June 6, 2024 upon approval by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:11 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001415889-24-004109 · form4-02162024_090243.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 14, 2024, provided the optionee continues to provide service to the Company. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:31 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001062993-23-018391 · form4.xml · derivative · entry 2 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-07-07 F2 · date: Performance-based stock option granted on July 8, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F2 · derivative.exercise_date: Performance-based stock option granted on July 8, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:31 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-23-018391 · form4.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-15 F1 · date: Performance-based stock option granted on February 16, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on February 16, 2022 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:17 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 540,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004900 · form4.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 540,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 15:52 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001062993-22-016245 · form4.xml · derivative · entry 1 Feller Faye · CIK 0001937361 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing July 9, 2022, provided the optionee continues to provide services to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.